Project/Area Number |
16K10688
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory surgery
|
Research Institution | Kitasato University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
天野 英樹 北里大学, 医学部, 講師 (60296481)
江島 耕二 北里大学, 医学部, 准教授 (30327324)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 肺再生 / VEGF / VEGFR1 / VEGFR1-Kシグナル / 片肺摘出 / 代償性肺再生 / VEGFR1-TK シグナル / 肺摘出 / 外科 / 再生医学 |
Outline of Final Research Achievements |
Vascular endothelial growth factor (VEGF) and its receptors promote lung regeneration. The present study was to examine the role of VEGF receptor 1 (VEGFR1) signaling in lung regeneration after pneumonectomy. After left pneumonectomy, the right lung weight was higher in VEGF transgenic mice than wild-type (WT) mice and was suppressed significantly in mice injected with a VEGF neutralizing antibody and in VEGF receptor-1 tyrosine kinase-deficient mice (TK-/- mice). The mobilization of progenitor cells expressing VEGFR1+ cells from bone marrow and the recruitment of these cells to lung tissue were also suppressed in the TK-/- mice. WT mice transplanted with bone marrow from TK-/- transgenic GFP+ mice had significantly lower numbers of GFP+/aquaporin 5 +, , GFP+/surfactant protein A+, and GFP+/VEGFR1+ cells than WT mice transplanted with bone marrow from WTGFP+ mice. Overall, these results suggest that VEGF signaling contributes to compensatory lung growth by mobilizing VEGFR1+ cells.
|
Academic Significance and Societal Importance of the Research Achievements |
片肺摘出の刺激によりVEGFR1チロシンキナーゼシグナルが骨髄組織のストローマ因子を活性化させ、骨髄組織からVEGFR1陽性細胞が動員され肺に集積しVEGFの産生を促すことで肺の代償性再生を増強している可能性が示唆された。本研究の成果は、骨髄由来のVEGFR-1発現細胞の気管内もしくは静脈内投与が、肺再生に関する新たな治療法になり得ることが期待される。
|